




- (51) **International Patent Classification:**
C07C 275/06 (2006.01) C07D 213/00 (2006.01)
C07C 275/26 (2006.01)
- (21) **International Application Number:** PCT/US2012/026315
- (22) **International Filing Date:** 23 February 2012 (23.02.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
PCT/CN2011/00298
25 February 2011 (25.02.2011) CN
61/466,070 22 March 2011 (22.03.2011) US
- (71) **Applicant (for all designated States except US):**
HELSINN HEALTHCARE SA [CH/CH]; Via Pian
Scairolo 9, CH-6912 Lugano/Pazzallo (CH).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **GARCIA RUBIO, Silvina** [UY/US]; 7 Bellflower Ct., Princeton, NJ 08540 (US). **PIETRA, Claudio** [IT/IT]; Via Scalabrini 56, Como (IT). **GIULIANO, Claudio** [IT/IT]; Via Prudeniana 28/A, Como (IT). **LI, Zhigang** [CN/CN]; Room 601 (21), No768 Meihua Road, Pudong District, Shanghai, 201204 (CN).
- (74) **Agent:** **SULLIVAN, Clark, G.**; Arnall Golden Gregory LLP, 171 17th Street NW, Suite 2100, Atlanta, GA 30363 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report (Art. 21(3))
- (88) **Date of publication of the international search report:**
24 April 2014

(54) **Title:** ASYMMETRIC UREAS AND MEDICAL USES THEREOF

(57) **Abstract:** Compounds of Formula (I), known as asymmetric ureas, are useful for preventing and/or treating diseases that are pathophysiologically related to the ghrelin receptor in a subject. Method of treating a disease that is mediated by the ghrelin receptor, comprising administering to said subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or adduct thereof. Pharmaceutical compositions for preventing and/or treating diseases which are pathophysiologically related to ghrelin receptor in a subject, comprising a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or adduct thereof, and one or more pharmaceutically acceptable excipients.